Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD

Rang în acțiuni #31694
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Preț acțiune
$0.24909259
Capitalizare de piață
$11.77M
Schimbare (1 zi)
1.94%
Schimbare (1 an)
-14.21%
Țară
BE
Tranzacționează Celyad Oncology S.A. (CYAD)

Categorie

Healthcare
Istoricul randamentului dividendelor pentru Celyad Oncology S.A. (CYAD)
Randamentul dividendelor (TTM) pentru Celyad Oncology S.A. (simbol acțiune: CYAD) la data de 2026 este: 0
Randamentul mediu al dividendelor în ultimii 5 ani: 0.00%
Istoric al randamentului dividendelor pentru Celyad Oncology S.A. (CYAD) între 2026 și 2026
Randamentul dividendelor la sfârșitul fiecărui an (TTM)
An Randamentul dividendelor Schimbă
Nu sunt suficiente date pentru perioada selectată.
Randamentele dividendelor (TTM) pentru companii similare sau concurente
Companie Randamentul dividendelor Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.17%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL